| Identification | Back Directory | [Name]
N-(9,10-dioxo-9,10-dihydroanthracen-2-yl)benzamide | [CAS]
52869-18-8 | [Synonyms]
SSAA09E3
N-(9,10-dioxo-9,10-dihydroanthracen-2-yl)benzamide | [EINECS(EC#)]
660-768-3 | [Molecular Formula]
C21H13NO3 | [MDL Number]
MFCD00157867 | [MOL File]
52869-18-8.mol | [Molecular Weight]
327.333 |
| Hazard Information | Back Directory | [Description]
SSAA09E3 is a novel inhibitor of SARS-CoV replication, acting by preventing fusion of the viral membrane with the host cellular membrane. | [Uses]
SSAA09E3 is a SARS-CoV entry inhibitor that inhibits SARS/HIV pseudotyped virus entry with an EC50 of 9.7 μM in 293T cells and inhibits SARS-CoV infection of Vero cells with an EC50 of 0.15 μM[1][2]. | [storage]
4°C, protect from light | [References]
[1] Ghosh AK, et al. Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics. ChemMedChem. 2020 Jun 4;15(11):907-932. DOI:10.1002/cmdc.202000223
[2] Adedeji AO, et al. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013 Jul;87(14):8017-28. DOI:10.1128/JVI.00998-13 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|